MAZE (Maze Therapeutics) Moat Score: 5/10 (As of Jul. 02, 2026)


MAZE Maze Therapeutics Inc MAZE
14 GF Score
Price $30.60
! 2 Warning Signs
View Full Analysis

What is Maze Therapeutics Moat Score?

Maze Therapeutics MAZE +2.79% 14 Moat Score is 5 as of Jul. 02, 2026. GuruFocus rates MAZE with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 1,400 Biotechnology companies, Maze Therapeutics ranks better than 96.71% on this metric.

Maze Therapeutics has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Maze Therapeutics has Narrow Moat: Maze Therapeutics Inc has a solid narrow moat due to its focus on innovative R&D and valuable intellectual property. However, the biotech industry is competitive, and the company lacks strong brand strength or significant regulatory barriers.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Maze Therapeutics might have Narrow Moat - Solid narrow moat.

Maze Therapeutics  (NAS:MAZE) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Maze Therapeutics Moat Score Related Terms

MAZE vs AVBP, DMRA, CAPR: Moat Score Comparison

For the Biotechnology subindustry, Maze Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Maze Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Maze Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Maze Therapeutics's Moat Score falls into.


MAZE
14GF Score
Maze Therapeutics Inc MAZE
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Maze Therapeutics (MAZE) has a Moat Score of 5 as of Jul. 02, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Maze Therapeutics ranks #46 out of 1400 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Maze Therapeutics' Moat Score too high?
Maze Therapeutics' current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. Maze Therapeutics' value of 5 is 150% above this industry median. Based on the distribution chart, Maze Therapeutics ranks #46 out of 1400 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Maze Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Maze Therapeutics' Moat Score compare to AVBP and DMRA?
According to the Biotechnology industry distribution chart, Maze Therapeutics ranks #46 out of 1400 companies for Moat Score. This places Maze Therapeutics in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Maze Therapeutics' value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Maze Therapeutics's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maze Therapeutics's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maze Therapeutics stock overvalued right now?
Maze Therapeutics (MAZE) has a current Moat Score of 5. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. Maze Therapeutics' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Maze Therapeutics (MAZE), the current Moat Score is 5 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Maze Therapeutics Business Description

Address 171 Oyster Point boulevard, Suite 300, South San Francisco, CA, USA, 94080
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
14GF Score

Get the complete analysis for MAZE

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$30.60
Price